
June 7, 2014	Web Version \| Share with a colleague \| eNews Subscribe	You are subscribed to the FormularyWatch eNews

ASCO: Bortezomib-based regimen shows improved outcomes for mantle cell lymphoma

A bortezomib (Velcade)-based regimen significantly improved progression free survival (PFS) and consistently improved secondary efficacy end points in previously untreated mantle cell lymphoma (MCL) patients compared to standard therapy, according to data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Read more

ASCO: Second-line treatment with ramucirumab with standard docetaxel extends survival in NSCLC

Ramucirumab (Cyramza) combined with docetaxel (Taxotere) extended overall survival 1.4 months in patients with non-small cell lung cancer (NSCLC) when compared to standard second-line therapy (docetaxel alone), according to data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Read more

ASCO: Ceritinib shrank tumors in most patients with ALK+ NSCLC regardless of prior ALK treatment

Ceritinib (Zykadia) previously known as LDK378, shrank tumors in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC), including those who had received previous treatment with an ALK inhibitor as well as patients receiving one for the first time, according to data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Results were also observed in patients with ALK+ NSCLC who entered the study with brain metastases. Read more

#icymi